A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy

Guido Finazzi, Alessandro M. Vannucchi, Vincenzo Martinelli, Marco Ruggeri, Francesco Nobile, Giorgina Specchia, Enrico Maria Pogliani, Odoardo Maria Olimpieri, Giuseppe Fioritoni, Caterina Musolino, Daniela Cilloni, Piera Sivera, Giovanni Barosi, Maria Chiara Finazzi, Silvia Di Tollo, Tim Demuth, Tiziano Barbui, Alessandro Rambaldi

Research output: Contribution to journalArticle

Abstract

Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia vera (PV), unresponsive to the maximum tolerated doses (MTD) of hydroxycarbamide (HC), were treated with Givinostat (50 or 100 mg/d) in combination with MTD of HC. The European LeukaemiaNet response criteria were used to assess the primary endpoint after 12 weeks of treatment. Complete or partial response was observed in 55% and 50% of patients receiving 50 or 100 mg of Givinostat, respectively. Control of pruritus was observed in 64% and 67% of patients in the 50 and 100 mg groups, respectively. The combination of Givinostat and HC was well tolerated: eight patients (18%) discontinued, four in each treatment arm; grade 3 adverse events were reported in one patient (4·5%) in each treatment arm. The combined use of Givinostat and HC was safe and clinically effective in HC-unresponsive PV patients.

Original languageEnglish
Pages (from-to)688-694
Number of pages7
JournalBritish Journal of Haematology
Volume161
Issue number5
DOIs
Publication statusPublished - Jun 2013

Keywords

  • Givinostat
  • Histone-deacetylase inhibitor
  • Hydroxycarbamide
  • Myeloproliferative neoplasm
  • Polycythaemia vera

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy'. Together they form a unique fingerprint.

  • Cite this

    Finazzi, G., Vannucchi, A. M., Martinelli, V., Ruggeri, M., Nobile, F., Specchia, G., Pogliani, E. M., Olimpieri, O. M., Fioritoni, G., Musolino, C., Cilloni, D., Sivera, P., Barosi, G., Finazzi, M. C., Tollo, S. D., Demuth, T., Barbui, T., & Rambaldi, A. (2013). A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. British Journal of Haematology, 161(5), 688-694. https://doi.org/10.1111/bjh.12332